NO20034874D0 - Aerosolformuleringer for pulmonaradministrasjon av medikamenter for frembringelse av en systemisk effekt - Google Patents

Aerosolformuleringer for pulmonaradministrasjon av medikamenter for frembringelse av en systemisk effekt

Info

Publication number
NO20034874D0
NO20034874D0 NO20034874A NO20034874A NO20034874D0 NO 20034874 D0 NO20034874 D0 NO 20034874D0 NO 20034874 A NO20034874 A NO 20034874A NO 20034874 A NO20034874 A NO 20034874A NO 20034874 D0 NO20034874 D0 NO 20034874D0
Authority
NO
Norway
Prior art keywords
drugs
produce
pulmonary administration
aerosol formulations
systemic effect
Prior art date
Application number
NO20034874A
Other languages
English (en)
Other versions
NO20034874L (no
Inventor
Rebecca Jaine Davies
David Ganderton
David Andrew Lewis
Brian John Meakin
Gaetano Brambilla
Alessandra Ferraris
Original Assignee
Chiesi Farma Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiesi Farma Spa filed Critical Chiesi Farma Spa
Publication of NO20034874D0 publication Critical patent/NO20034874D0/no
Publication of NO20034874L publication Critical patent/NO20034874L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
NO20034874A 2002-03-01 2003-10-31 Aerosolformuleringer for pulmonaradministrasjon av medikamenter for frembringelse av en systemisk effekt NO20034874L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02004786A EP1340492A1 (en) 2002-03-01 2002-03-01 Aerosol formulations for pulmonary administration of medicaments having systemic effects
PCT/EP2003/001962 WO2003074023A1 (en) 2002-03-01 2003-02-26 Aerosol formulations for pulmonary administration of medicaments to produce a systemic effect

Publications (2)

Publication Number Publication Date
NO20034874D0 true NO20034874D0 (no) 2003-10-31
NO20034874L NO20034874L (no) 2003-12-23

Family

ID=27675679

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20034874A NO20034874L (no) 2002-03-01 2003-10-31 Aerosolformuleringer for pulmonaradministrasjon av medikamenter for frembringelse av en systemisk effekt

Country Status (27)

Country Link
US (1) US20050129621A1 (no)
EP (2) EP1340492A1 (no)
JP (1) JP2005519094A (no)
KR (1) KR20040091050A (no)
CN (2) CN1638731A (no)
AR (2) AR038643A1 (no)
AT (1) ATE488224T1 (no)
AU (1) AU2003215597B2 (no)
BR (1) BR0303348A (no)
CA (1) CA2477879C (no)
DE (1) DE60334973D1 (no)
EA (1) EA008571B1 (no)
ES (1) ES2358293T3 (no)
GE (1) GEP20063985B (no)
HR (1) HRP20040751A2 (no)
IL (1) IL163842A0 (no)
MA (1) MA27107A1 (no)
MX (1) MXPA04008370A (no)
NO (1) NO20034874L (no)
NZ (1) NZ535019A (no)
PE (1) PE20030949A1 (no)
PL (1) PL372261A1 (no)
TN (1) TNSN04148A1 (no)
TW (1) TW200304833A (no)
UA (2) UA81238C2 (no)
WO (1) WO2003074023A1 (no)
ZA (3) ZA200406918B (no)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010031244A1 (en) * 1997-06-13 2001-10-18 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
IT1303788B1 (it) * 1998-11-25 2001-02-23 Chiesi Farma Spa Formulazioni di aerosol medicinali.
DZ2947A1 (fr) * 1998-11-25 2004-03-15 Chiesi Farma Spa Inhalateur à compteur de dose sous pression.
US6315985B1 (en) * 1999-06-18 2001-11-13 3M Innovative Properties Company C-17/21 OH 20-ketosteroid solution aerosol products with enhanced chemical stability
IT1317720B1 (it) * 2000-01-07 2003-07-15 Chiesi Farma Spa Dispositivo per la somministrazione di aerosol dosati pressurizzati inpropellenti idrofluoroalcani.
IT1318514B1 (it) * 2000-05-12 2003-08-27 Chiesi Farma Spa Formulazioni contenenti un farmaco glucocorticosteroide per iltrattamento di patologie broncopolmonari.
US20060257324A1 (en) * 2000-05-22 2006-11-16 Chiesi Farmaceutici S.P.A. Pharmaceutical solution formulations for pressurised metered dose inhalers
HU230804B1 (hu) * 2000-05-22 2018-06-28 Chiesi Farmaceutici S.P.A Gyógyászati célú stabil aeroszol összetétel, inhalátor az aeroszol pontos adagolásához és eljárás ennek feltöltésére
ATE267591T1 (de) * 2001-07-02 2004-06-15 Chiesi Farma Spa Optimierte tobramycin-formulierung zur aerosolbildung
JP2005523905A (ja) * 2002-03-01 2005-08-11 キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ ホルモテロール（ｆｏｒｍｏｔｅｒｏｌ）超微細調合物
EP1415647A1 (en) * 2002-10-23 2004-05-06 CHIESI FARMACEUTICI S.p.A. "Long-acting beta-2 agonists ultrafine formulations"
EP1452179A1 (en) * 2003-02-27 2004-09-01 CHIESI FARMACEUTICI S.p.A. Novel medicament combination of a highly potent long-lasting beta2-agonist and a corticosteroid
GB0311701D0 (en) * 2003-05-21 2003-06-25 Karib Kemi Pharm Liited Improved metered dose inhaler product
JP2007505831A (ja) * 2003-09-15 2007-03-15 ベクトゥラ・リミテッド 肺吸入による、早漏を治療するための医薬品組成物
EP1595531A1 (en) * 2004-05-13 2005-11-16 CHIESI FARMACEUTICI S.p.A. Stable pharmaceutical solution formulations for pressurized metered dose inhalers
IL177103A0 (en) * 2004-02-27 2006-12-10 Chiesi Farma Spa Stable pharmaceutical solution formulations for pressurized metered dose inhalers
AU2005259523B2 (en) * 2004-07-02 2011-06-09 Boehringer Ingelheim International Gmbh Aerosol suspension formulations containing TG 227 ea or TG 134 a as a propellant
RU2457832C2 (ru) * 2005-09-25 2012-08-10 Сипла Лимитед Состав на основе тровентола
US20070243262A1 (en) * 2005-12-21 2007-10-18 Hurley Kevin P Stable S-nitrosothiol formulations
DE102006017320A1 (de) * 2006-04-11 2007-10-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Aerosolsuspensionsformulierungen mit TG 227 ea oder TG 134 a als Treibmittel
EP2011534A1 (en) * 2007-07-03 2009-01-07 CHIESI FARMACEUTICI S.p.A. Metered dose inhaler actuator
PE20090907A1 (es) * 2007-07-21 2009-08-05 Boehringer Ingelheim Int Nuevos medicamentos pulverulentos que contienen tiotropio y salmeterol, asi como lactosa como excipiente
WO2009049159A1 (en) 2007-10-10 2009-04-16 Parion Sciences, Inc. Delivering osmolytes by nasal cannula
US8555875B2 (en) * 2008-12-23 2013-10-15 Map Pharmaceuticals, Inc. Inhalation devices and related methods for administration of sedative hypnotic compounds
CN103052392A (zh) * 2010-07-12 2013-04-17 赛利亚医药公司 通过氨基糖苷气雾给药治疗肺部感染
EP3170846A1 (en) 2010-09-22 2017-05-24 The Board of Regents of The University of Texas System Novel block copolymer and micelle compositions and methods of use thereof
US8945605B2 (en) * 2011-06-07 2015-02-03 Parion Sciences, Inc. Aerosol delivery systems, compositions and methods
WO2012170677A1 (en) 2011-06-07 2012-12-13 Parion Sciences, Inc. Methods of treatment
EP2794577A4 (en) * 2011-12-20 2015-05-20 Map Pharmaceuticals Inc AUXILIARY AEROSOL FORMULATION
GB201402513D0 (en) 2014-02-13 2014-04-02 Cardiff Scintigraphics Ltd Pressurised metered dose inhalers and method of manufacture
CA3111682A1 (en) 2014-06-26 2015-12-30 Island Breeze Systems Ca, Llc Mdi related products and methods of use
WO2016187156A1 (en) * 2015-05-21 2016-11-24 Island Breeze Systems Ca, Llc Propellant based metered dose inhaler and food applicators and applicators
US11129848B2 (en) 2017-08-08 2021-09-28 Perricone Hydrogen Water Company, Llc Medication enhancement using hydrogen
GB201912686D0 (en) * 2019-09-04 2019-10-16 Reown Pharma Inc Pharmaceutical composition
US11123365B2 (en) 2019-11-18 2021-09-21 Perricone Hydrogen Water Company, Llc Compositions comprising palmitoylethanolamide and hydrogen water, and methods thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2273835A1 (en) * 1996-12-04 1998-06-11 Bioglan Ireland (R & D) Limited Pharmaceutical compositions and devices for their administration
US20010031244A1 (en) * 1997-06-13 2001-10-18 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
GB2326334A (en) * 1997-06-13 1998-12-23 Chiesi Farma Spa Pharmaceutical aerosol compositions
US6309623B1 (en) * 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
US6284282B1 (en) * 1998-04-29 2001-09-04 Genentech, Inc. Method of spray freeze drying proteins for pharmaceutical administration
IT1303788B1 (it) * 1998-11-25 2001-02-23 Chiesi Farma Spa Formulazioni di aerosol medicinali.
DZ2947A1 (fr) * 1998-11-25 2004-03-15 Chiesi Farma Spa Inhalateur à compteur de dose sous pression.
EP1143930B8 (en) * 1999-09-11 2008-03-19 Glaxo Group Limited Pharmaceutical formulation of fluticasone propionate
IT1317720B1 (it) * 2000-01-07 2003-07-15 Chiesi Farma Spa Dispositivo per la somministrazione di aerosol dosati pressurizzati inpropellenti idrofluoroalcani.
IT1317846B1 (it) * 2000-02-22 2003-07-15 Chiesi Farma Spa Formulazioni contenenti un farmaco anticolinergico per il trattamentodella broncopneumopatia cronica ostruttiva.
CA2402020C (en) * 2000-03-09 2006-08-29 Gw Pharma Limited Pharmaceutical compositions
BR0005797A (pt) * 2000-03-20 2001-10-16 Abbott Lab Métodos para o tratamento de disfunção sexual com apomorfina em nìveis de concentração plasmática especificados
IT1318514B1 (it) * 2000-05-12 2003-08-27 Chiesi Farma Spa Formulazioni contenenti un farmaco glucocorticosteroide per iltrattamento di patologie broncopolmonari.
HU230804B1 (hu) * 2000-05-22 2018-06-28 Chiesi Farmaceutici S.P.A Gyógyászati célú stabil aeroszol összetétel, inhalátor az aeroszol pontos adagolásához és eljárás ennek feltöltésére
JP2005523905A (ja) * 2002-03-01 2005-08-11 キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ ホルモテロール（ｆｏｒｍｏｔｅｒｏｌ）超微細調合物
EP1595531A1 (en) * 2004-05-13 2005-11-16 CHIESI FARMACEUTICI S.p.A. Stable pharmaceutical solution formulations for pressurized metered dose inhalers

Also Published As

Publication number Publication date
EA200401006A1 (ru) 2005-04-28
MA27107A1 (fr) 2004-12-20
EP1480616B1 (en) 2010-11-17
AR101593A2 (es) 2016-12-28
AU2003215597B2 (en) 2008-07-31
JP2005519094A (ja) 2005-06-30
CN1638731A (zh) 2005-07-13
NZ535019A (en) 2006-09-29
PL372261A1 (en) 2005-07-11
TW200304833A (en) 2003-10-16
BR0303348A (pt) 2004-07-13
CN101502500A (zh) 2009-08-12
KR20040091050A (ko) 2004-10-27
GEP20063985B (en) 2006-12-11
MXPA04008370A (es) 2004-11-26
ZA200406918B (en) 2006-06-28
EP1340492A1 (en) 2003-09-03
DE60334973D1 (de) 2010-12-30
ZA200406917B (en) 2006-06-28
CA2477879A1 (en) 2003-09-12
ES2358293T3 (es) 2011-05-09
ZA200406919B (en) 2006-06-28
AR038643A1 (es) 2005-01-19
WO2003074023A1 (en) 2003-09-12
PE20030949A1 (es) 2004-01-02
EA008571B1 (ru) 2007-06-29
HRP20040751A2 (en) 2004-12-31
CA2477879C (en) 2011-05-03
AU2003215597A1 (en) 2003-09-16
UA81238C2 (en) 2007-12-25
EP1480616A1 (en) 2004-12-01
US20050129621A1 (en) 2005-06-16
NO20034874L (no) 2003-12-23
ATE488224T1 (de) 2010-12-15
UA80695C2 (en) 2007-10-25
IL163842A0 (en) 2005-12-18
TNSN04148A1 (en) 2007-03-12

Similar Documents

Publication Publication Date Title
NO20034874L (no) Aerosolformuleringer for pulmonaradministrasjon av medikamenter for frembringelse av en systemisk effekt
NO20033343D0 (no) Farmasöytiske doseringsformer av epothiloner for oral administrasjon
FI7617U1 (fi) Amorfisen aktiivisen ainesosan stabiloitu farmaseuttinen valmiste
IS7612A (is) Staðbundin lyfjablanda
NO20042842L (no) Farmasoytiske formuleringer av platina-derivat
NO20043866L (no) Farmasoytisk formulering av IRESSA omfattende et vannopploselig cellulosederivat
CY2018005I2 (el) Απο του στοματος φαρμακοτεχνικες μορφες της κλαντριβινης
AU2001231000A1 (en) Dry powder formulations of antihistamine for nasal administration
EE200200439A (et) Tsentraalsete kannabinoidiretseptorite antagonisti kasutamine ravimtoodete valmistamiseks, aitamaksloobuda tubakatarbimisest
NO20025592L (no) Kontinuerlig produksjon av farmasöytisk granulering
DK1399127T3 (da) Olopatadinformuleringer til topisk administration
PT1501534E (pt) Formulacoes farmaceuticas
HRP20040545A2 (en) Pharmaceutical compositions of orally active taxane derivatives having enhanced bioavailability
CY2011014I1 (el) Φαρμακοτεχνικες μορφες σταθερου φαρμακευτικου διαλυματος για υπο πιεση μετρημενης δοσης συσκευες εισπνοης
AU2002211863A1 (en) Bile-acid derived compounds for providing sustained systemic concentrations of drugs after oral administration
ITMI20011337A0 (it) Composizioni farmaceutiche orali a rilascio modificato del principio attivo
NO20035438L (no) Farmasoytisk formulering for effektiv administrering av apomorfin, 6aR-(-)-N-propyl-norapomorfin og deres derivater og prodrugs derav
NO20043832L (no) Oral fast losningsformulering av en darlig vannloselig aktiv substans
NO20014738D0 (no) Tolperisonholdig farmasöytisk preparat for oral administrering
EE200200075A (et) Peroraalselt ja paikselt manustatavad farmatseutilised kompositsioonid
DK1225902T3 (da) Ciclesonidholdigt farmaceutisk præparat til administration til slimhinden
NO20025394D0 (no) Formuleringer inneholdende et glukokorticoid legemiddel for behandling av bronkopulmonire sykdommer
FI20000780A (fi) Peroraalinen lääkemuoto lääkeaineen hallituksi vapauttamiseksi
ITMI20001827A0 (it) Medicamento antinfiammatorio
NO20084860L (no) Stabile farmasøytiske preparater av 2-aza-bisyklo-[3,3,0]-oktan-3-karboksylsyrederivater

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application